

BNSSG Shared Care Guidance

Please complete all sections

Section 1: Heading

Drug	Testosterone gel
Amber <i>three months</i>	
<p>Testosterone may be initiated by secondary care or a menopause specialist in primary care</p> <p>A specialist in menopause for the purposes of testosterone prescribing is a British Menopause Society accredited specialist or equivalent prescriber who can demonstrate that they have received training in, and have clinical experience of, treating women with testosterone preparations. This could therefore be a GP or ANP or Pharmacist Independent Prescriber working in primary care if they meet the following criteria:</p> <ol style="list-style-type: none"> 1. A healthcare professional who holds a recognised menopause qualification such as: <ul style="list-style-type: none"> ▪ BMS Management of the Menopause Certificate (<i>Please note: The BMS Management of the Menopause Certificate is a new qualification that replaces the BMS PPMC Certificate. Trainees who are already registered for the BMS PPMC Certificate should complete their competency-based training to achieve certification.</i>) ▪ FSRH Menopause Care Professional Certificate (MCPC) <p>and</p> <ol style="list-style-type: none"> 2. Maintains skills and knowledge in line with GMC / NMC / GPhC requirements for revalidation <ul style="list-style-type: none"> ▪ To be a prescriber with knowledge of the drug regimens and side effects ▪ Attends a national or regional menopause scientific update session at least once every three years (e.g. BMS, FSRH, primary care forum, etc); ▪ Provides a minimum of 100 menopause related consultations per year, of which at least 50 are new. 	
Indication	<p>For women with the following:</p> <ol style="list-style-type: none"> 1. Low libido causing distress and 2. Ongoing symptoms despite optimised oestrogen and progesterone HRT and 3. All other causes (biopsychosocial approach) have been excluded and 4. Total Testosterone <1.5nmol/L

Section 2: Treatment Schedule

Usual dose and frequency of administration (<i>Please indicate if this is licensed or unlicensed and any relevant dosing information</i>)	<p>First Line (as enables metred dosage):</p> <ul style="list-style-type: none"> ○ Tostran 2% gel – 1 pump alternate days (10mg per metred dose). ○ A 60g canister should last 240 days or 8 months. ○ Cost of a year's treatment at above dosage - £43.54 ○ Easier application – reducing potential confusion over correct dosing in some patients.
----------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BNSSG Shared Care Guidance

	<p>Second Line</p> <ul style="list-style-type: none"> ○ Testogel 1% gel - 1/8th of a 40.5mg sachet applied daily (5mg / day) ○ £47.29 for a year's treatment at the above dosage. ○ The sachet, once opened, should be closed with a clip and refrigerated. ○ As a daily preparation, can provide a steadier / more stable absorption level which can be beneficial in providing symptom control in some women, especially those with Premature Ovarian Insufficiency (POI). Off label indication.
<p>Route and formulation</p>	<p>Transdermal.</p> <p>The medication is spread over the upper thighs in the morning – alternating the place of application on each day of use. It is not necessary to rub into the skin. The alcohol evaporates and the testosterone is absorbed into the upper layers of the skin. The testosterone is then gradually released into the circulation over the next 24 hours. Allow drying for at least 3 – 5 minutes before dressing. Wash hands with soap and water after applications. Do not rub skin where testosterone is applied against another female's skin as transference can occur which can lead to signs of androgen excess in females.</p>
<p>Duration of treatment</p>	<p>Once efficacy established, assessment should occur with the annual oestrogen and progestogen HRT review. Assess symptoms and need for ongoing use. Assessment should include:</p> <ul style="list-style-type: none"> - A testosterone level which should be <2.7nmol/L (Normal range 0.3 – 2.7nmol/L) - Review of androgenic side effects (acne, hirsutism, male pattern balding) - Review of ongoing symptom control - Review of need for ongoing use; after 5 years of use, offer washout and review of symptoms / testosterone levels 3 months later <p>If any concerns, contact gynaecology advice and guidance.</p>

Section 3: Monitoring

Please give details of any tests that are required before or during treatment, including frequency, responsibilities (please state whether they will be undertaken in primary or secondary care), cause for adjustment and when it is required to refer back to the specialist.

<p>Baseline tests - where appropriate</p>

BNSSG Shared Care Guidance

- Total testosterone level and sex hormone binding globulin (8-10am sample)
- Allows calculation of free androgen index at baseline ($FAI = \text{total testosterone} \times 100 / SHBG$). Although this should be reported by the laboratories when testosterone is requested with SHBG, see link for FAI calculator [Free Androgen Index \(FAI\) Calculator \(mdapp.co\)](http://mdapp.co)
- Levels to be taken prior to the first prescription, 3 months after starting and 6 monthly during continuing therapy. If treatment successful during initial trial period and FAI remains <9%, to be continued in primary care with support from secondary care if needed.
- Women ideally to have bloods taken in primary care 1 week prior to review at 3 months (as a GP delegated request) to enable continued prescribing at the clinic appointment.
- Ask women not to use testosterone on the morning of the test – can cause false positive supra-physiological levels
- Women with a total testosterone <1.5nmol/L at baseline (therapeutic range) can gain benefit from use and do not tend to go above the normal female range with use.

Subsequent tests - where appropriate *(Please indicate who takes responsibility for taking bloods and interpreting results)*

The GP will be responsible for:

1. Issuing of prescription and adjustment of dose according to the protocol, or on specialist advice, after test results are known to the prescriber.
2. Notification to the specialist of any changes in the patient's condition or any adverse drug reactions.
3. Non-compliance with medications or monitoring: Contacting the patient to ascertain the reason for non-attendance for routine blood tests if more than one test is missed. Communication with the patient that non-attendance for blood testing will lead to withdrawal of the medication.
4. Severe side effects/potential overdose: urgent referral to the specialist if required.
5. Referral of the patient back to specialist if the medicine becomes less effective, and medical conditions / oestrogen HRT has been optimised.

Test	Frequency	Who by	Action/management
Total testosterone level and sex hormone binding globulin (8-10am sample)	At 3 months, 6 months and 12 months	Secondary Care or menopause specialist	If treatment successful during initial trial period and FAI remains <9%, to be continued in primary care with support from secondary care if needed
Review of efficacy and side effects	At 3 months, 6 months and 12 months	Secondary care or menopause specialist	
	12 monthly once stable	GP Practice	1. If patient reports efficacious symptom control and:

BNSSG Shared Care Guidance

<p>Total testosterone level and sex hormone binding globulin (8-10am sample) one week prior to review with GP. FAI should be reported by the laboratory, but see link for FAI calculator Free Androgen Index (FAI) Calculator (mdapp.co)</p>			<p>a.) Total testosterone >2.7nmol/L</p> <p>Stop testosterone and send advice and guidance query. SHBG level and current oestrogen dose to be included in A&G query.</p> <p><i>NB Ensure patient has not used testosterone on the day of testing, if so repeat test.</i></p> <p>2. If patient reports reduced efficacy of symptom control and: FAI <4% Send advice and guidance query</p> <p>Include total testosterone level, SHBG level and current oestrogen dose in A&G query</p>
<p>Review with GP regarding symptom control and presence of androgenic side effects</p>	<p>12 monthly once stable</p>	<p>GP Practice</p>	<ul style="list-style-type: none"> - Review of androgenic side effects (acne, hirsutism, male pattern balding) - Review of ongoing symptom control - Review of need for ongoing use; after 5 years of use, - Offer a trial without testosterone and review symptoms and repeat testosterone levels after 3 months

Section 4: Side Effects

Please list only the most pertinent side effects and management. Please provide guidance on when the GP should refer back to the specialist. For everything else, please see BNF or SPC.

	Side effect	Frequency/severity	Action/management
	<p>Side effects and management</p>	<p>Skin reaction, acne, hirsutism</p>	<p>1in10</p>
<p>Clitoromegaly, enlarged labia, deepening voice</p>		<p>Rare, occurs with prolonged, supraphysiological levels and can be irreversible.</p>	<p>Urgent FAI and stop testosterone after test. Discuss with menopause specialist.</p>
<p>Referral back to specialist</p>	<p>Review criteria:</p> <ul style="list-style-type: none"> • Troublesome effects such as headaches, acne, hirsutism • Onset of cardiovascular disease or hormone sensitive cancers 		

Section 5: Other Issues

BNSSG Shared Care Guidance

(e.g. Drug Interactions, Contra-indications, Cautions, Special Recommendations)

Please list only the most pertinent action for GP to take (For full list please see BNF or SPC)

Issues	<p>Contra-indications</p> <ul style="list-style-type: none"> • Patients discontinuing oestrogen hormone replacement therapy • Supraphysiological free androgen index (>9%) • Active liver disease • Pregnancy • Clinical evidence of androgen excess such as clitoromegaly, enlarged labia, deepening voice • Oestrogen sensitive conditions such as oestrogen receptor cancers, unstable lupus / catamenial epilepsy. <p>Precautions</p> <p>Women suffering from severe cardiac, hepatic or renal insufficiency or ischaemic heart disease; treatment with testosterone may cause severe complications characterised by oedema with, or without, congestive cardiac failure. In such case, treatment must be stopped immediately. In addition, diuretic therapy may be required.</p> <p>Interactions (see SPC for full list http://www.medicines.org.uk/emc/)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Oral anticoagulants</td> <td>Monitoring of INR recommended particularly when started / stopped</td> </tr> <tr> <td>Corticosteroids</td> <td>Increased risk of oedema. Co-administer with caution</td> </tr> <tr> <td>Thyroxine-binding globulin</td> <td>Androgens may decrease concentrations of thyroxin-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged however, and there is no clinical evidence of thyroid dysfunction.</td> </tr> <tr> <td>Insulin</td> <td>Improved insulin sensitivity may occur in patients treated with androgens who achieve normal testosterone plasma concentrations following replacement therapy.</td> </tr> </table>	Oral anticoagulants	Monitoring of INR recommended particularly when started / stopped	Corticosteroids	Increased risk of oedema. Co-administer with caution	Thyroxine-binding globulin	Androgens may decrease concentrations of thyroxin-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged however, and there is no clinical evidence of thyroid dysfunction.	Insulin	Improved insulin sensitivity may occur in patients treated with androgens who achieve normal testosterone plasma concentrations following replacement therapy.
Oral anticoagulants	Monitoring of INR recommended particularly when started / stopped								
Corticosteroids	Increased risk of oedema. Co-administer with caution								
Thyroxine-binding globulin	Androgens may decrease concentrations of thyroxin-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged however, and there is no clinical evidence of thyroid dysfunction.								
Insulin	Improved insulin sensitivity may occur in patients treated with androgens who achieve normal testosterone plasma concentrations following replacement therapy.								
Reminder to ask patient about specific problems	As above								

Section 6: Advice to the patient

BNSSG Shared Care Guidance

Advice for prescribing clinician to inform patient

1. Alternating the place of application on each day of use.
2. Report any androgenic side effects
3. Ongoing prescription can only be provided if attend for annual testosterone levels

Section 7: Generic principles of shared care for **SECONDARY CARE**

Please do not amend.

Core responsibilities

1. Initiating treatment and prescribing for the length of time specified in **section 1**.
2. Undertaking the clinical assessment and monitoring for the length of time specified in **section 1** and thereafter undertaking any ongoing monitoring as detailed in **section 3**.
3. Communicate details of the above in 1 and 2 to GP within the first month of treatment. This information should be transferred in a timely manner.
4. Refer patients to GP and provide information of further action where appropriate e.g. if blood test is due.
5. To provide advice to primary care when appropriate.
6. Review concurrent medications for potential interaction prior to initiation of drug specified in **section 1**.
7. Stopping treatment where appropriate or providing advice on when to stop.
8. Reporting adverse events to the MHRA.
9. Reminder to ask patients about particular problems see **section 5**.

Section 8: Generic principles of shared care for **PRIMARY CARE**

Please do not amend.

Core responsibilities

1. Responsible for taking over prescribing after the length of time specified in **section 1**.
2. Responsible for any clinical assessment and monitoring if detailed in **section 3** after the length of time specified in **section 1**.
3. Review of any new concurrent medications for potential interactions.
4. Reporting adverse events to the MHRA.
5. Refer for advice to specialist where appropriate.
6. Reminder to ask patients about particular problems see **section 5**.

Section 9: Contact Details

Name	Organisation	Telephone Number	E mail address
Kristyn Manley, Menopause Specialist	University Hospitals Bristol and Weston	Gynaecology OPD is 0117 342 5793	Click here to enter details
Dr Tracy-Louise Appleyard, Gynaecologist	NBT	Gynaecology OPD is 0117 414 6791	Click here to enter details

Section 10: Document Details

Date prepared	October 2024, updated in December 2024
Prepared by	Kristyn Manley, Consultant Gynaecologist, UHBW and Anna Durbin and Karon Arnold, Interface Pharmacists, BNSSG ICB.
Date approved by JFG	October 24

BNSSG Shared Care Guidance

Date of review	October 27
Document Identification: Version	V10

Section 11: Collaboration

All shared care protocols should be BNSSG wide where possible. Specialists in any one discipline are encouraged to collaborate across the health community in preparing shared care guidance. Please give details

1. University Hospitals Bristol and Weston
2. North Bristol Trust

Section 12: References

Please list references

- Achilli *et al* (2017). Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. *Fertil Steril* 107(2): 475 - 482
- Beral *et al* (2019). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. *Lancet* 394: 1159 - 1168
- Davis *et al* (2019). Global consensus statement on the use of testosterone therapy for women. *J Clin Endocrinol* 104(10): 4660 – 4666
- Islam *et al* (2019). Efficacy and safety of testosterone therapy for women: a systematic review and meta-analysis of randomised controlled trials. *Lancet* 7(10): 754 – 766
- Maclaren K (2012). The safety of postmenopausal testosterone therapy. *Women's Health* 8(3): 263 - 275
- BMS Tool for Clinicians (www.thebms.org.uk/publications/tools-for-clinicians/testosterone-replacement-in-menopause/)
- ESHRE (2015). Management of women with premature ovarian insufficiency.
- NICE guideline (NG23). Menopause: diagnosis and management.